France AI in Drug Discovery Market

France AI in Drug Discovery Market Insights Forecasts to 2035

• The France AI in Drug Discovery Market Size was estimated at USD 48.10 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 31.08% from 2025 to 2035
• The France AI in Drug Discovery Market Size is Expected to Reach USD 944.42 Million by 2035

According to a research report published by decision advisor & Consulting, the France AI in Drug Discovery Market is anticipated to reach USD 944.42 million by 2035, growing at a CAGR of 31.08% from 2025 to 2035. The market is propelled by the government's strategic funding support and investment in AI research and infrastructure, the implementation of the EU regulatory framework, the establishment of organized pathways for the integration of AI in clinical trials, and the development of strategic public-private partnerships between French AI companies and multinational pharmaceutical giants, all of which have accelerated market adoption.

Market Overview

The AI in drug discovery market refers to the use of AI technology to improve efficiency, accuracy and speed in the discovery of new drugs, and it is a part of pharmaceutical R&D. It includes the adoption of machine learning, deep learning and analyzation of data to analyze complicated biological data, predict molecular interaction and help support decision making through the life of drug development. Additionally, the commitment to AI development is offering a solid foundation for AI drug discovery innovation through strategic policy templates and record investment initiatives.  The French government announced in February 2025 that 109 billion euros ($112.5 billion) in private sector investments would be made in France to advance AI in the coming years. Data center development is expected to receive a significant portion of these resources.  This type of government assistance puts France at the forefront of AI-driven pharmaceutical research globally, helps companies accelerate R&D efforts, and attracts talent from around the world. Maintaining long-term competitiveness on the global market requires a strategic investment approach focused on creating sustainable ecosystems that combine academic distinction with business success. Public funding systems are especially designed to support high-risk, high-return research projects that traditional private funding might overlook, enabling ground-breaking discoveries in challenging therapeutic fields. This comprehensive government assistance program maintains innovation and scientific quality while providing French AI drug discovery companies with the financial assurance and strategic backing they need to compete with well-funded foreign competitors.

Report Coverage

This research report categorizes the market for the France AI in drug discovery market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France AI in drug discovery market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France AI in drug discovery market.

Driving Factors

The growth of the France AI in drug discovery market is primarily attributed to the formation of collaborations between French AI companies and international pharmaceutical multinational companies, which spark innovation and accelerate market growth by forming mutually beneficial partnerships. Collaborations provide exposure for French AI companies to large datasets, clinical expertise, and reginal distribution systems while pharmaceutical partners received advanced AI technology and innovative drug candidates. Collaborations are more than just a financial investment and include knowledge sharing, regulatory expertise, and collaborative research programs that decrease the time frame for develop drug candidates discovered using AI. French companies are purposefully extending their global footprint with offices in key biotech centers like London to access heterogeneous pools of talent and locate in proximity to prime pharmaceutical markets.

Restraining Factors

The market for AI in drug discovery in France is constrained by issues like the difficulty of integrating AI with legacy research systems and the lack of access to high-quality, standardized biomedical datasets.  Rapid adoption is hampered, particularly in clinical settings, by regulatory uncertainties surrounding AI validation and data privacy compliance.  Implementation is further hampered by the high expense of AI infrastructure and a lack of interdisciplinary talent that combines data science and pharmaceutical knowledge.

Market Segmentation

The France AI in drug discovery market share is classified into offering and application.

• The software segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France AI in drug discovery market is segmented by offering into software and services. Among these, the software segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The market for artificial intelligence in drug discovery in France is expanding rapidly as a result of the growing use of sophisticated platforms for target identification, molecular simulation, and predictive modeling.  AI-driven software is being used by pharmaceutical companies and research institutions to shorten drug development timelines, cut costs, and improve candidate selection accuracy. Scalable deployment is further supported by growing cloud infrastructure and government-backed digital transformation projects.

• The target identification segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France AI in drug discovery market is segmented by application into preclinical testing, drug optimization and repurposing, target identification, candidate screening, and others. Among these, the target identification segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth due to high-throughput biological data is becoming more widely available and machine learning algorithms that can identify new therapeutic targets are being integrated.  AI speeds up early-stage drug development, lowers attrition rates, and allows for accurate mapping of disease mechanisms.  Growth is further fueled by industry-academia partnerships, supportive government initiatives, and growing demand for personalized medicine.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France AI in drug discovery market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• NovAliX
• OSE Immunotherapeutics
• Phost’in Therapeutics
• Others

Recent Developments:

• In May 2025, France's Sorbonne University and Qubit Pharmaceuticals, a spin-off from Sorbonne, had unveiled the "most powerful in the world" AI model for molecular simulation in pharmaceutical chemistry. The model, named FeNNix-Biol, had reportedly been able to model and simulate molecular behavior with accuracy and speed “unprecedented until then,” according to the team responsible for the model.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at France, regional, and country levels from 2020 to 2035. decision advisor has segmented the France AI in Drug Discovery Market based on the below-mentioned segments:France AI in Drug Discovery Market, By Offering

• Software
• Services

France AI in Drug Discovery Market, By Application

• Preclinical Testing
• Drug Optimization and Repurposing
• Target Identification
• Candidate Screening
• Others

FAQ’s

Q: What is the France AI in drug discovery market size?

A: France AI in Drug Discovery Market is expected to grow from USD 48.10 million in 2024 to USD 944.42 million by 2035, growing at a CAGR of 31.08% during the forecast period 2025-2035.

Q: What are the key growth drivers of the market?

A: Strategic government spending, EU regulatory support, public-private partnerships, and growing demand for quicker, more affordable drug development using cutting-edge machine learning technologies are driving France's AI in drug discovery market.

Q: What factors restrain the France AI in drug discovery market?

A: The market for AI in drug discovery in France is constrained by a lack of interdisciplinary talent in bioinformatics, high implementation costs, regulatory uncertainty, restricted access to high-quality datasets, and data privacy issues.

Q: Who are the key players in the France AI in drug discovery market?

A: NovAliX, OSE Immunotherapeutics, Phost’in Therapeutics, Others.

Q: Who are the target audiences for this market report?

A: The report targets market players, investors, end-users, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).